Cardiologists Shocked by New FDA Alert on Clopidogrel-PPI Interaction

November 17, 2009 — The FDA has today issued a new public-health warning on the possible interaction between clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis) and the proton-pump inhibitor (PPI) omeprazole (Prilosec, Procter & Gamble) [1,2]. The alert states: "New data show that when clopidogrel and omeprazole are taken together, the effectiveness of clopidogrel is reduced. Patients at risk for heart attacks or strokes who use clopidogrel to prevent blood clots will not get the full effect of this medicine if they are also taking omeprazole."

But the timing of the this alert appears peculiar, given that just a few weeks ago, what was said to be the definitive answer to this issue--the only randomized clinical trial on the interaction--was reported, showing absolutely no hint of any reduction in effect of clopidogrel in patients taking omeprazole.

Cardiologists contacted by heartwire were surprised at the new FDA announcement.

游客，如果您要查看本帖隐藏内容请回复

clopidogrel + omeprazole ,联用, 前者降低药效(FDA). Cardiologist shocked ..

学习学习，谢谢。

奥美拉唑是否对氯吡格雷产生影响？学习学习。